Trelagliptin — A Novel Once-Weekly DPP-4 Inhibitor Advancing Type 2 Diabetes Care

      Trelagliptin (brand names: Trelaglip® and Zafatek) is a novel, once-weekly oral medication that is reshaping the landscape of type 2 diabetes management. Recently approved in Japan and India, it belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the body’s natural incretin hormones—GLP-1 and GIP-to improve blood sugar control. Unlike traditional DPP-4 inhibitors that require daily intake, Trelagliptin’s extended duration of action allows for just one tablet per week, significantly improving treatment adherence, reducing pill burden, and supporting a better quality of life for people with diabetes.

      Mechanistically, Trelagliptin inhibits the DPP-4 enzyme to prolong the activity of incretin hormones, which help stimulate insulin secretion and suppress glucagon release-only when blood glucose is elevated. This glucose-dependent action reduces the risk of hypoglycemia, a common concern with many diabetes therapies. Clinical studies, including those using continuous glucose monitoring (CGM), have shown that Trelagliptin significantly lowers glycemic variability and postprandial spikes, providing smoother blood glucose control. This stability is critical in preventing long-term complications and supports overall metabolic balance.

      Beyond glucose control, Trelagliptin offers potential cardiovascular benefits by protecting blood vessels from the damaging effects of blood sugar fluctuations. As cardiovascular disease remains a leading cause of death in diabetes patients, this added protection is clinically meaningful. Originally developed by Takeda Pharmaceutical Company and launched in Japan, Trelagliptin entered the Indian market in 2025 under the brand Trelaglip®, marketed by Zuventus Healthcare. Its introduction marks a significant advancement in accessible, convenient, and effective diabetes care, particularly in countries with high diabetes prevalence and the need for patient-friendly treatment options.

Read More